<DOC>
	<DOC>NCT01331408</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy and safety of Macrolane for volume restoration and shaping of the buttocks.</brief_summary>
	<brief_title>A Study to Evaluate Efficacy and Safety of Macrolane VRF30 for Volume Restoration and Contouring of the Buttocks</brief_title>
	<detailed_description />
	<criteria>â‰¥ 20 years old willing to undergo augmentation therapy of the buttocks where a maximum total injected volume of 400 ml of the study product is judged by the Investigator to be enough to achieve full correction understand and comply with the requirements of the study be willing to understand and comply with the requirements of the study be willing to abstain from esthetic surgery and esthetical augmentation procedures (other than the study treatment) between the umbilicus and the knees. be a male or nonpregnant, non breastfeeding female. give written informed consent to participate in the study Active skin disease, inflammation or related conditions Tumors or premalign tissue disorder near or on the area to be treated scar tissue in the area to be treated subjects seeking corrections for other body parts then the buttocks anywhere between the umbilicus and the knees subjects with human immunodeficiency virus (HIV) associated lipodystrophy subjects having undergone liposuction within 6 months prior to inclusion BMI &lt;20 or expected instable weight insufficient tissue cover in the area to be treated excessive skin laxity in the area to be treated other injectable implant or permanent implant near or in the area to be treated previous radiation therapy of tumors near or in the area to be treated concomitant anticoagulant therapy, antiplatelet therapy or a history of bleeding disorders. a presence or history of connective tissue diseases ongoing immunosuppressive therapy known allergies or hypersensitivity reactions towards anesthetics previous inflammatory or hypersensitivity reactions towards products containing Hyaluronic acid any condition which in the opinion of the investigator makes the subject unsuitable for inclusion use of any investigational drugs or devices within 30 days prior to inclusion.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>